Han Ying compensation by year
GYRE THERAPEUTICS Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $338,614 | $309,018 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $2,503,401 | $0 |
| Non-equity incentive | $35,000 | $35,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $11,125 | $9,297 |
| Total | $2,888,140 | $353,315 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GYRE THERAPEUTICS, INC. DEF 14A filed April 27, 2026, accession 0001140361-26-017124, and prior-year filings.
How this page was built: the GYRE THERAPEUTICS, INC. filed document, accession 0001140361-26-017124. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 622 | — | $6.93 |
| Option | 227,333 | — | $9.98 |
Per the Outstanding Equity Awards at Fiscal Year-End table in GYRE THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
GYRE THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Weiguo Ye | Chief Operating Officer | $5,023,749 |
| Ping Zhang | Interim Chief Executive Officer | $4,096,623 |
| Han Ying · this page | Senior Vice President, Science and Former Chief Executive Officer | $353,315 |
| Ruoyu Chen | Chief Financial Officer | $285,583 |
Board service
GYRE THERAPEUTICS board · FY2023–FY2024| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | — | — | — | — | — |
| FY2023 | $10,500 | — | $10,578 | — | $21,078 |
Each year as the company reported it in GYRE THERAPEUTICS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: GYRE THERAPEUTICS pays directors a $40,000 cash retainer. As stated in GYRE THERAPEUTICS's FY2024 proxy.
Han Ying's compensation dossier, GYRE THERAPEUTICS
You have read Han Ying's totals and holdings. The dossier adds each equity grant GYRE THERAPEUTICS disclosed for Han Ying and GYRE THERAPEUTICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full GYRE THERAPEUTICS compensation record
free company briefThis page is one person within GYRE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order GYRE THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GYRE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.